Tace-2 trial 

A Randomised Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination with Transarterial Chemoembolisation in Hepatocellular Cancer.

The TACE-2 Trial aims to determine if the addition of sorafenib to TACE (performed according to a standardised protocol using DC Bead loaded with doxorubicin) is superior to TACE alone in the treatment of hepatocellular carcinoma.

TACE-2 has so far randomised 7 patients.

The trial aims to recruit 412 patients over 3 years from centres in the UK, Ireland, France and Italy.

If your site is interested in participating, please contact us or complete the Site Registration Form and return to the trials office.